StockNews.AI
AVDL
StockNews.AI
176 days

Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3

1. Avadel will host a conference call on March 3, 2025. The event will discuss Q4 and 2024 financials. 2. The update includes a live audio webcast and a 90-day replay availability. Investors can register online. 3. The call details are provided on the company’s website. It highlights a routine earnings review.

Earnings
-1.76%Current Return
VS
-0.5%S&P 500
$8.24502/24 04:15 PM EDTEvent Start
$8.102/25 10:48 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

The announcement is a scheduled earnings update, which is typically priced in; however, surprises during the call could cause short-term volatility. Historically, routine calls only cause significant movement if results deviate from expectations.

How important is it?

While the earnings update is a critical corporate event for AVDL, scheduled announcements tend to have a moderated impact unless unexpected results emerge.

Why Short Term?

Earnings updates generally affect near-term price movements, with immediate market reactions seen after similar calls in the past.

Related Companies

February 24, 2025 16:05 ET  | Source: Avadel Pharmaceuticals plc DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, March 3, 2025, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2024. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. About Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years and older with narcolepsy. For more information, please visit www.avadel.com. Investor Contact: Austin Murtagh Precision AQAustin.Murtagh@precisionaq.com (212) 698-8696 Media Contact: Lesley StanleyReal Chemistrylestanley@realchemistry.com (609) 273-3162

Related News